Seems some may may be getting spooked by what’s happened with the likes of FTT today and selling. The difference RGS has compared with those certain stocks is that we are doing deals with partners and will have licensing deals with larger partners for trials going forwards.
That is a significant difference between us and those who have had to go it all alone. What it tells you is that early trial results show enough potential that others are willing to buy in and wear the risk, they have much larger teams and have gone through the outcomes, modelled future outcomes and direction and will pay for exposure, in our first instance = Progenza...
RGS Price at posting:
19.5¢ Sentiment: Buy Disclosure: Held
